Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Repligen Corporation - Common Stock (NQ:RGEN)

155.06 +2.46 (+1.61%)
Streaming Delayed Price Updated: 10:17 AM EDT, Oct 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Repligen Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Federal Reserve Signals Further Rate Cuts Amidst Worsening Labor Market and Divided Opinions
Washington D.C. – The Federal Reserve has sent clear signals of a continued dovish pivot, with Chair Jerome Powell indicating the likelihood of two additional quarter-point interest rate cuts before... 
Via MarketMinute
Topics Artificial Intelligence Bonds Credit Cards
Myriad Genetics, Omnicell, Globus Medical, Repligen, and Teleflex Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. 
Via StockStory
Topics Economy Government World Trade
Analyst Expectations For Repligen's Future
 
Via Benzinga
Thermo Fisher Scientific Soars on Strategic Wins, Market Optimism
Thermo Fisher Scientific Inc. (NYSE: TMO) experienced a robust surge in its stock value today, October 1, 2025, climbing an impressive 9.79% as market optimism swelled around a series of recent... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
What 8 Analyst Ratings Have To Say About Repligen
 
Via Benzinga
Why Is Repligen (RGEN) Stock Soaring Today
Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 6.6% in the afternoon session after HSBC initiated coverage on the stock with a 'Buy' rating and a $150 price... 
Via StockStory
Topics Government
Repligen, BrightSpring Health Services, Danaher, Thermo Fisher, and Amgen Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry. 
Via StockStory
Topics Government
1 Volatile Stock to Target This Week and 2 Facing Challenges
Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor... 
Via StockStory
3 Reasons to Sell RGEN and 1 Stock to Buy Instead
Over the past six months, Repligen’s shares (currently trading at $123.26) have posted a disappointing 15.1% loss, well below the S&P 500’s 15.5% gain. This might have investors contemplating their... 
Via StockStory
Topics Stocks
Drug Development Inputs & Services Stocks Q2 Results: Benchmarking Repligen (NASDAQ:RGEN)
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Repligen (NASDAQ:RGEN) and its peers. 
Via StockStory
This Sarepta Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
 
Via Benzinga
Small-Cap and Value Stocks Stage a Powerful Comeback: A Market Rebalancing Act Underway
After years of being overshadowed by their large-cap growth counterparts, small-cap and value stocks are experiencing a significant resurgence, signaling a potential seismic shift in market leadership.... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Repligen (RGEN) Stock Is Up, What You Need To Know
Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 4.4% in the afternoon session after investment firm Stifel reiterated its Buy rating and maintained a $207.00 price... 
Via StockStory
Anchored at 4%: Why the Steady 10-Year Treasury Yield is Key to Unlocking the Fed's Stimulus Power
The U.S. financial markets are currently at a critical juncture, with the stability of the 10-year Treasury yield hovering steadfastly around the 4% mark. This apparent calm in long-term borrowing... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
1 Cash-Producing Stock with Exciting Potential and 2 We Avoid
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
Why Repligen (RGEN) Stock Is Down Today
Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) fell 3.5% in the afternoon session after Jefferies lowered its price target on the stock. 
Via StockStory
Topics Artificial Intelligence Economy
Bond Yields Tumble as Investors Brace for Aggressive Fed Rate Cuts
U.S. Treasury yields have recently experienced a significant decline, with the benchmark 10-year Treasury note falling to its lowest levels since April 2025. This sharp dip in yields reflects a... 
Via MarketMinute
Topics Bonds Economy Supply Chain
3 Cash-Heavy Stocks We Find Risky
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow. 
Via StockStory
Repligen, Revvity, Avantor, Fortrea, and Azenta Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices rebounded, as Fed Chair Jerome Powell delivered dovish remarks at the much-awaited Jackson Hole symposium. Powell suggested... 
Via StockStory
Topics Economy
3 of Wall Street’s Favorite Stocks with Warning Signs
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because... 
Via StockStory
3 Unprofitable Stocks We Steer Clear Of
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth. 
Via StockStory
3 Cash-Producing Stocks We Think Twice About
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
NeoGenomics, Progyny, Repligen, Revvity, and Waters Corporation Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer... 
Via StockStory
Topics Economy
AMN Healthcare Services, NeoGenomics, Acadia Healthcare, BrightSpring Health Services, and Repligen Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed... 
Via StockStory
Topics Bonds Economy Stocks
RGEN Q2 Deep Dive: Chromatography and Filtration Drive Growth, Guidance Lifted Amid New Modalities Uncertainty
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) announced better-than-expected revenue in Q2 CY2025, with sales up 14.8% year on year to $182.4 million. The company’s full-year... 
Via StockStory
1 Safe-and-Steady Stock on Our Buy List and 2 We Turn Down
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
Repligen Stock Outlook: Risk Skewed To The Downside Through 2026
Repligen stock has been in a prolonged downtrend, and Adhishthana principles suggest more weakness ahead. Here's what investors should track... 
Via Benzinga
Why Repligen (RGEN) Stock Is Up Today
Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 7.8% in the morning session after the company reported strong second-quarter 2025 financial results and raised its... 
Via StockStory
Topics Artificial Intelligence Lawsuit
Repligen Corp (NASDAQ:RGEN) Q2 2025 Earnings: Revenue Beat Offsets EPS Miss as Stock Rises in Pre-Market
Repligen Corp's Q2 2025 earnings show revenue beat estimates at $182.4M, but EPS missed at $0.37. Stock rose 2.65% pre-market amid strong order growth. 
Via Chartmill
Repligen’s (NASDAQ:RGEN) Q2 Sales Top Estimates, Full-Year Sales Guidance is Optimistic
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 14.8% year on year to $182.4 million. The... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.